Kailera Therapeutics, Inc. (NASDAQ:KLRA) Given Consensus Recommendation of "Moderate Buy" by Brokerages

Key Points

• Kailera Therapeutics received a “Moderate Buy” consensus rating from eight analysts, with five buy ratings, one strong buy, one hold and one sell. The average 12-month price target is $42.75.
• Institutional investors established significant new positions in the second quarter, including Wellington Management’s approximately $64.3 million stake and Frazier Life Sciences Management’s roughly $24.2 million investment.
• The stock opened at $13.94, near its 52-week low of $13.90, after the company reported a quarterly loss of $1.09 per share—$0.35 worse than analysts’ expectations. Analysts forecast a full-year loss of $3.89 per share.

Kailera Therapeutics, Inc. (NASDAQ:KLRA - Get Free Report) has received a consensus recommendation of "Moderate Buy" from the eight ratings firms that are currently covering the company, MarketBeat Ratings reports. One equities research analyst has rated the stock with a sell rating, one has assigned a hold rating, five have issued a buy rating and one has given a strong buy rating to the company. The average 12-month target price among brokerages that have issued a report on the stock in the last year is $42.75.

Several research firms have recently weighed in on KLRA. Wall Street Zen cut shares of Kailera Therapeutics from a "hold" rating to a "sell" rating in a report on Saturday, May 30th. Weiss Ratings assumed coverage on shares of Kailera Therapeutics in a research report on Friday, August 14th. They issued a "sell (d)" rating on the stock.

Institutional Trading of Kailera Therapeutics

A number of institutional investors have recently modified their holdings of KLRA. California State Teachers Retirement System acquired a new stake in Kailera Therapeutics in the 2nd quarter valued at approximately $309,000. Tidal Investments LLC acquired a new position in Kailera Therapeutics during the 2nd quarter worth approximately $309,000. Squarepoint Ops LLC acquired a new position in Kailera Therapeutics during the 2nd quarter worth approximately $993,000. Frazier Life Sciences Management L.P. acquired a new stake in shares of Kailera Therapeutics in the second quarter valued at approximately $24,233,000. Finally, Wellington Management Group LLP bought a new stake in shares of Kailera Therapeutics in the second quarter worth $64,308,000.

Kailera Therapeutics Stock Performance

NASDAQ KLRA opened at $13.94 on Monday. Kailera Therapeutics has a one year low of $13.90 and a one year high of $28.23. The firm has a market capitalization of $1.81 billion and a price-to-earnings ratio of -0.00. The stock's 50-day simple moving average is $17.89.

Kailera Therapeutics (NASDAQ:KLRA - Get Free Report) last issued its quarterly earnings data on Wednesday, August 12th. The company reported ($1.09) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.74) by ($0.35). As a group, analysts anticipate that Kailera Therapeutics will post -3.89 EPS for the current fiscal year.

Kailera Therapeutics Company Profile

Kailera Therapeutics, Inc is a clinical-stage biopharmaceutical company focused on developing medicines for obesity and related metabolic diseases. The company's programs are designed to address the substantial medical needs associated with excess weight and metabolic disorders.

Kailera's lead product candidate is KAIL-001, a long-acting glucagon-like peptide-1 (GLP-1) receptor agonist intended for the treatment of obesity and potentially related conditions. The company is advancing its pipeline through clinical development and regulatory activities, although its products remain investigational and are not yet approved for commercial use.

The company's operations are centered on the development of therapies for global markets.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.